• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era
Int Immunopharmacol. 2023 Mar 3;117:109952. doi: 10.1016/j.intimp.2023.109952. Online ahead of print.ABSTRACTThymosin alpha 1 (Tα1) is a highly conserved 28 amino-acid peptide naturally occurring in the thymus and plays critical roles in T cell maturity and differentiation. Its synthetic form, thymalfasin, has been approved by various regulatory agencies in the treatment of hepatitis B viral infection and as an enhancer of vaccine response in immune-compromised populations. In China, it has also widely utilized in patients with cancer and severe infections, as well as the emergency use during (Severe Acute Respiratory Syn...
Source: International Immunopharmacology - March 5, 2023 Category: Allergy & Immunology Authors: Li Mao Source Type: research

Unraveling the Role of < em > Scutellaria baicalensis < /em > for the Treatment of Breast Cancer Using Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation
In this study, network pharmacology, molecular docking, and molecular dynamics simulation are combined to reveal the most active compound in Scutellaria baicalensis and to explore the interaction between the compound molecule and the target protein in the treatment of breast cancer. In total, 25 active compounds and 91 targets were screened out, mainly enriched in lipids in atherosclerosis, the AGE-RAGE signal pathway of diabetes complications, human cytomegalovirus infection, Kaposi-sarcoma-associated herpesvirus infection, the IL-17 signaling pathway, small-cell lung cancer, measles, proteoglycans in cancer, human immuno...
Source: Atherosclerosis - February 25, 2023 Category: Cardiology Authors: Yanqi Jiao Chengcheng Shi Yao Sun Source Type: research

Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey
CONCLUSIONS: ICIs administration in patients with cancer and HBV or HCV infection is of concern for most of the surveyed European oncologists. Nonetheless, active screening and treatment of viral hepatitis should be improved. Data in this specific setting are needed for an evidence-based management and should be generated by broadening inclusion criteria of clinical trials to allow the enrollment of patients with HBV and HCV.PMID:36687558 | PMC:PMC9853354 | DOI:10.1016/j.jtocrr.2022.100446
Source: Clinical Lung Cancer - January 23, 2023 Category: Cancer & Oncology Authors: Marco Tagliamento Jordi Remon Matteo Giaj Levra Andrea De Maria Paolo Bironzo Benjamin Besse Silvia Novello Laura Mezquita Source Type: research

Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment
Conclusion: Due to high risks of HBV reactivation in HBsAg-positive TKI users, NUC prophylaxis can be considered. However, in patients with resolved HBV infection, such risks are lower, and therefore regular monitoring is recommended.PMID:36615034 | DOI:10.3390/jcm12010231
Source: Clinical Lung Cancer - January 8, 2023 Category: Cancer & Oncology Authors: Po-Hsin Lee Yen-Hsiang Huang Yu-Wei Hsu Kun-Chieh Chen Kuo-Hsuan Hsu Ho Lin Teng-Yu Lee Jeng-Sen Tseng Gee-Chen Chang Tsung-Ying Yang Source Type: research

Pembrolizumab-induced acute exacerbation of hepatitis D
Z Gastroenterol. 2022 Nov 14. doi: 10.1055/a-1934-1940. Online ahead of print.ABSTRACTA 55-year-old man was treated with combined immunochemotherapy (pembrolizumab, carboplatin and pemetrexed) because of non-small cell lung cancer (NSCLC). In addition, the patient had a medical history of chronic hepatitis B/D virus infection and cystic echinococosis. The viral hepatitis co-infection was treated with pegylated interferon (IFN)-alpha and tenofovir in the past (non-response after treatment), followed by maintenance therapy with tenofovir. Since the echinococosis was inactive, there was no need for specific treatment. The the...
Source: Zeitschrift fur Gastroenterologie - November 15, 2022 Category: Gastroenterology Authors: Anna Fichtl Annika Beck Thomas Seufferlein Eugen Zizer Source Type: research

Efficacy and Safety of PD-1 Immune Checkpoint Inhibitors in Locally Advanced and Advanced Non-Small Cell Lung Cancer Patients with Chronic Infection
Conclusions The PD-1 inhibitor showed an acceptable toxicity profile and moderate efficacy on NSCLC patients with chronic infection, but still has the potential to increase the incidence of hepatitis.PMID:35231913 | DOI:10.1159/000523854
Source: Cell Research - March 1, 2022 Category: Cytology Authors: Zhiting Zhao Ran Hu Yan Chen Guoren Zhou Shaorong Yu Jifeng Feng Source Type: research

The Spectrum of Malignant Neoplasms among Liver Transplant Recipients: Sociodemographic Factors, Mortality, and Hospital Burden
Conclusions: Malignancies were frequent among elderly patients and predominantly in males. Lymphoproliferative diseases were the most prevalent malignancy types, followed by respiratory/lung cancer- which showed the highest mortality risk of all cancers. LTX patients are at increased risk of head and neck cancers, skin cancers, lymphoma, tumors, and Myelodysplastic syndrome compared to non-LTX patients.PMID:35165515 | PMC:PMC8795812 | DOI:10.7150/ijms.66533
Source: Cancer Control - February 15, 2022 Category: Cancer & Oncology Authors: Maryam Haider Anusha Bapatla Rana Ismail Ahmed J Chaudhary Sana Iqbal Syed M Haider Source Type: research

Pages: 1  2  3  4  5